Aclaris Therapeutics, Inc. (ACRS) Is At $24.63 Formed Wedge; John Hancock Tax-advantaged Global Shareholder Yield Fund (HTY) Has 1.25 Sentiment

The stock increased 1.35% or $0.12 during the last trading session, reaching $8.99. About 66,021 shares traded. John Hancock Investments – John Hancock Tax-Advantaged Global Shareholder Yield Fund (HTY) has declined 7.77% since January 7, 2017 and is downtrending. It has underperformed by 24.47% the S&P500.

Aclaris Therapeutics, Inc. (ACRS) formed wedge down with $23.40 target or 5.00% below today’s $24.63 share price. Aclaris Therapeutics, Inc. (ACRS) has $759.46 million valuation. The stock increased 1.82% or $0.44 during the last trading session, reaching $24.63. About 177,537 shares traded. Aclaris Therapeutics, Inc. (NASDAQ:ACRS) has risen 25.57% since January 7, 2017 and is uptrending. It has outperformed by 8.87% the S&P500.

Among 6 analysts covering Aclaris Therapeutics (NASDAQ:ACRS), 5 have Buy rating, 0 Sell and 1 Hold. Therefore 83% are positive. Aclaris Therapeutics had 14 analyst reports since November 2, 2015 according to SRatingsIntel. The firm has “Buy” rating by Jefferies given on Friday, July 28. The company was initiated on Friday, September 30 by JMP Securities. As per Friday, August 12, the company rating was maintained by Jefferies. The firm has “Buy” rating by Jefferies given on Monday, November 2. The firm has “Buy” rating given on Monday, June 26 by Jefferies. As per Monday, September 19, the company rating was maintained by Jefferies. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) earned “Outperform” rating by Leerink Swann on Tuesday, November 29. The firm earned “Buy” rating on Friday, June 10 by Guggenheim. The firm earned “Buy” rating on Tuesday, November 7 by Cantor Fitzgerald. The stock of Aclaris Therapeutics, Inc. (NASDAQ:ACRS) earned “Buy” rating by Citigroup on Monday, November 2.

Analysts await Aclaris Therapeutics, Inc. (NASDAQ:ACRS) to report earnings on March, 21. They expect $-0.90 EPS, down 83.67% or $0.41 from last year’s $-0.49 per share. After $-0.63 actual EPS reported by Aclaris Therapeutics, Inc. for the previous quarter, Wall Street now forecasts 42.86% negative EPS growth.

Clenar Muke Llc holds 0.07% of its portfolio in John Hancock Investments – John Hancock Tax-Advantaged Global Shareholder Yield Fund for 169,424 shares. National Planning Corp owns 15,095 shares or 0.03% of their US portfolio. Moreover, Laurion Capital Management Lp has 0.01% invested in the company for 124,279 shares. The Georgia-based Advisory Services Network Llc has invested 0% in the stock. Ameriprise Financial Inc, a Minnesota-based fund reported 57,721 shares.